Dyne Therapeutics Inc. reports first-quarter results Thursday, with investors watching for updates on the clinical-stage biotech’s path toward commercializing its lead therapy for Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results